Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Rating) was the target of a significant increase in short interest in the month of May. As of May 15th, there was short interest totalling 4,720,000 shares, an increase of 5.8% from the April 30th total of 4,460,000 shares. Based on an average trading volume of 666,600 shares, […]
Finepoint Capital LP cut its position in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Rating) by 3.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 517,287 shares of the biotechnology company’s stock after selling 19,614 shares during the period. […]
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Rating) has earned an average recommendation of “Moderate Buy” from the twelve research firms that are presently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month target […]
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Rating)’s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $28.91 and traded as high as $32.67. Cerevel Therapeutics shares last traded at $32.11, with a volume of 335,337 shares traded. Analysts Set New Price Targets […]
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Rating) was the target of a significant drop in short interest in April. As of April 30th, there was short interest totalling 4,460,000 shares, a drop of 10.1% from the April 15th total of 4,960,000 shares. Based on an average daily trading volume, of 666,200 shares, the days-to-cover […]